Background The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) is a randomized clinical trial to evaluate whether prophylactic laser treatment to the retina can prevent the complications of the advanced stage of Age-Related Macular Degeneration (AMD), the leading cause of irreversible blindness.
Methods CAPT is conducted in 23 clinical centers and in three central resource centers. The primary outcome measure is change in visual acuity; secondary outcomes include the incidence of complications of AMD, changes in other measures of visual functioning and vision-related quality of life. In total, 1052 patients with two high-risk eyes were enrolled. One eye was randomized to receive laser treatment and the other eye to observation. All patients were treated immediately after randomization and again at 12 months, dependent on clinical status. All patients are followed via study visits and telephone calls for a minimum of five years. Study visit procedures include established tests of visual function conducted by examiners masked to the treatment assignment of each eye, a biomicroscopic examination by CAPTophthalmologists, and photographs of each eye taken according to protocol and assessed by masked graders in a centralized Photograph Reading Center.
Results This paper describes the CAPT study, including study rationale, operational structure, and measures implemented to ensure standardization of assessments, adherence to protocol, quality assurance, and maintaining follow-up. Several features related to study design and procedures that are specific to CAPT are highlighted, including clinic selection and judgements regarding patient eligibility.
Conclusions An intervention that can reduce the risk of advanced AMD by 30% in the eyes of people with two high-risk eyes may halve the rate of bilateral blindness from AMD. It would also yield substantial savings in expenditures devoted to treating advanced AMD and the disability it causes, and enhance the quality of life for people at risk.
Get full access to this article
View all access options for this article.
References
1.
Tielsch JM. Vision problems in the U.S.Schaumburg, IL: Prevent Blindness America, 1994.
2.
Sommer A, Tielsch JM, Katz J et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med1991; 14: 1412–1417.
3.
Leibowitz HM, Krueger DE, Maunder LR et al. The Framingham Eye Study Monograph. Survey Ophthalmol1980; 24: 335–610.
4.
Klein R, Klein BE, Linton KLP. Prevalence of agerelated maculopathy: The Beaver Dam Eye Study. Ophthalmology1992; 99: 933–945.
5.
Sorsby A. Reports on public health and medical subjects, No. 114. London: Her Majesty's Stationery Of' ce, 1966.
6.
Department of Health and Human Services; National Institutes of Health. Age-related macular degeneration: Status of research. Report to Congress, 1997.
7.
Prevent Blindness America. Vision problems in the U.S. Prevalence of adult vision impairment and age-related eye disease in America. Schaumburg, IL: Prevent Blindness America, 2002.
8.
Venkataraman K, Herron T. Annual direct cost of illness of age-related macular degeneration in the US: early estimates of societal burden, 2003. Invest Opthalmol Vis Sci2003; 44: ARVOE-Abstract 3089-3098.
9.
Ferris FL. Senile macular degeneration: Review of epidemiologic features. Am J Ophthalmol1983; 118: 132–151.
10.
Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol1984; 102: 1640–1642.
11.
Gass JDM. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol1973; 90: 206–217.
12.
Smiddy WE, Fine SL. Prognosis of patients with bilateral macular drusen. Ophthalmology1984; 91: 271–277.
13.
Holz FG, Wolfensberger TJ, Piguet B et al. Bilateral macular drusen in age-related macular degeneration. Ophthalmology1994; 101: 1522–1528.
14.
Age-Related Eye Disease Study Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol2001; 119: 1417–1436.
15.
Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy after five years. Results from randomized clinical trials. Arch Ophthalmol1991; 109: 1109–1114.
16.
Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: Guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol1991; 109: 1242–1257.
17.
Macular Photocoagulation Study Group. Laser photocoagulation for subfoveal neovascular lesions of age-related macular degeneration: Updated findings from two clinical trials. Arch Ophthalmol1993; 111: 1200–1209.
18.
Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: Five year results from randomized clinical trials. Arch Ophthalmol1994; 112: 500–509.
19.
Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report 1. Arch Ophthalmol1999; 117: 1329–1345.
20.
Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials – TAP Report 2. Arch Ophthalmol2001; 119: 198–207.
21.
Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – Verteporfin in photodynamic therapy report 2. Am J Ophthalmol2001; 541–560.
22.
Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina2000; 20(4): 325–330.
23.
Nasser HE. Study: 2020 begins age of the elderly. USA Today21 May 1996; 4A-4A.
24.
Hawkins BS, Bressler NM. Estimate of number of people over age 65 in whom choroidal neovascularization associated with macular degeneration develops each year in the United States. Private communication. Based on prevalence and incidence rates from the Beaver Dam Eye Study, the Baltimore Longitudinal Study of Aging, the Waterman Study, and the Macular Photocoagulation Study.
25.
Lanchoney DM, Maguire MG, Fine SL. Model of the incidence and consequences of choroidal neovascularization secondary to age-related macular degeneration: Comparative effects of current treatment and potential prophylaxis on visual outcomes in high-risk patients. Arch Ophthalmol1998; 116: 1045–1052.
26.
Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen: short-term effects seen in pilot randomized clinical trial. Ophthalmology1998; 105: 11–23.
27.
Ho AC, Maguire MG, Yoken J et al. for the Choroidal Neovascularization Prevention Trial Research Group. Laser-induced drusen reduction improves visual function at 1 year. Ophthalmology1999; 106: 1367–1373.
28.
Kaiser RS, Berger JW, Maguire MG et al. for the Choroidal Neovascularization Prevention Trial Study Group. Laser burn intensity and the risk for choroidal neovascularization in the CNVPT Fellow Eye Study. Arch Ophthalmol2001; 119: 826–832.
29.
Little HL, Showman JM, Brown BW. A pilot randomized controlled study on the effect of laser photocoagulation of con‘ uent soft macular drusen. Ophthalmology1997; 104: 623–631.
30.
Frennesson IC, Nilsson SE. Effects of argon (green) laser treatment of soft drusen in early age-related maculopathy: a 6 month prospective study. Br J Ophthalmol1995; 79: 905–919.
31.
Frennesson C, Nilsson SE. Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications. Br J Ophthalmol1998; 82: 1169–1174.
32.
Olk RJ, Friberg TR, Stickney KL et al. Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study. Ophthalmology1999; 106: 2082–2090.
33.
Blackhurst DW, Maguire MG. The Macular Photocoagulation Study Group. Reproducibility of refraction and visual acuity measurement under a standard protocol. Retina1989; 9: 163–169.
34.
Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS Report Number 7. Ophthalmology1991; 98: 741–756.
35.
Age-Related Eye Disease Study Group. Manual of operations. In Bressler NM, Bressler SB, Gragoudas ES eds. Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol1987; 105: 209–213.
36.
Alexander MF, Maguire MG, Lietman TM, Snyder JR, Elman MJ, Fine SL. Assessment of visual function in patients with age-related macular degeneration and low visual acuity. Arch Ophthalmol1988; 106: 1543–1547.
37.
Rubin GS, Bandeen-Roche K, Huang GH, et al. The association of multiple visual impairments with self-reported visual disability: SEE project. Invest Ophthalmol & Vis Sci2001; 42: 64–72.
38.
Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. Clin Vision Sci1988; 3: 187–199.
39.
Mansfield JS, Legge GE, Bane MC. Psychophysics of reading; XV: Font effects in normal and low vision. Invest Ophthalmol & Vis Sci1996; 37: 1492–1501.
40.
Kupfer C. General principles for AIDS research [editorial; comment]. Arch Ophthalmol1996; 114: 862-862.
41.
Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol1993; 3: 1189–1199.
42.
Lachin JM. Power and sample size for the McNemar Test with application to matched case-control studies. Stat Med1992; 11: 93–113.
43.
Rosner B. Multivariate methods in ophthalmology with application to other paired-data situations. Biometrics1984; 40: 1025–1035.
44.
Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics1986; 42: 121–130.
45.
Glynn RJ, Rosner B. Comparison of alternative regression models for paired binary data. Stat Med1994; 13: 1023–1036.
Lin DY. MULCOX2: A general computer program for the Cox regression analysis of multivariate failure time data. Comput Meth Progr Biomed1993; 40: 279–293.
48.
Lin DY. Cox regression analysis of multivariate failure time data: the marginal approach. Statist Med1994; 13: 2233–2247.
49.
Madder LS. Simple approaches to assess the possible impact of missing outcome information on estimates of risk ratios, odds ratios and risk differences. Control Clin Trials2003; 24: 411–421.
50.
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics1979; 35: 549–556.
51.
Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika1983; 70: 649–653.
52.
DeMets DL, Lan KKG. Interim analysis: The alpha spending function approach. Stat Med1994; 13: 1341–1352.
53.
Qaqish BF, Liang K-Y. Marginal models for correlated binary responses with multiple classes and multiple levels of nesting. Biometrics1992; 48: 939–950.
